Sanofi (SNY) and Pfizer (PFE) Face Competition from German Bidder in Struggle for Medivation (MDVN) - Source
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Medivation's (Nasdaq: MDVN) competitive sale process is nearing its final stages, according to a source claiming to have knowledge of the matter. So far the San Francisco-based maker of XTANDI has received an offer from Pfizer (NYSE: PFE) and an improved offer from Sanofi (NYSE: SNY). The source also stated that a German drug company has entered the fray and plans to make a bid ahead of an upcoming deadline. The name of third bidder wasn't made known at this time.
The status of potential bids from Gilead (Nasdaq: GILD) and Celgene (Nasdaq: CELG), two companies mentioned as interested parties in previous media reports, wasn't discussed. Tomorrow is the deadline to submit an indication of interest.
Shares of Medivation last traded up 0.4% to $64.25.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vornado Realty Trust (VNO) Said to Mull Selling Washington Unit to JBG Via Spinoff - Bloomberg
- UPDATE: CIT Group (CIT) Hires Boston Consulting to Review Operations - DJ
- Time Warner (TWX) CEO says no one else has approached the company
Create E-mail Alert Related CategoriesHot M&A, Mergers and Acquisitions, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!